



## **Mersana Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference**

January 2, 2020

CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 38<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 16, 2020 at 9:00 a.m. PT.

A live webcast of the presentation will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). Archived replays will be available for approximately 90 days following the presentation.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to cancer patients. Mersana's lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

### **Contact:**

Investor & Media Contact  
Sarah Carmody, 617-844-8577  
[scarmody@mersana.com](mailto:scarmody@mersana.com)



Source: Mersana Therapeutics, Inc.